<keyword id="92247" type="COMPANY" weightage="20" keywordseo="Johnson-Johnson">Johnson &amp; Johnson</keyword>'s <keyword id="11735066" type="UNKNOWN" weightage="20" keywordseo="single-dose">single-dose</keyword> COVID-19 vaccine has been given Emergency Use approval in <keyword id="3658" type="COUNTRY" weightage="20" keywordseo="India">India</keyword>, <keyword id="700200" type="ORGANIZATION" weightage="20" keywordseo="Union-Health">Union Health</keyword> minister Mansukh Mandaviya said on Saturday. He said this will further boost the country's collective fight against the novel coronavirus infection. "India expands its vaccine basket! Johnson and Johnson's single-dose COVID-19 vaccine is given approval for Emergency Use in India. Now India has five <keyword id="2503801" type="ORGANIZATION" weightage="20" keywordseo="EUA">EUA</keyword> vaccines. This will further boost our nation's collective fight against #COVID19," the minister tweeted. The US-based pharmaceutical company had applied for <keyword id="9408526" type="UNKNOWN" weightage="20" keywordseo="emergency-use-authorisation">Emergency Use Authorisation</keyword> for its jab on Friday and was granted the approval the same day by the Drugs Controller General of India (DCGI). The five vaccines granted Emergency Use Authorisation in India are Serum Institute's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V, Moderna and now Johnson &amp; Johnson. SEE ALSO <a href="https://www.businessinsider.in/tech/news/google-is-now-using-chrome-as-another-security-layer-for-account-sign-ins/articleshow/84975356.cms">Google is now using Chrome as an added security layer for account sign-ins</a> <a href="https://www.businessinsider.in/stock-market/news/how-to-check-allotment-status-of-glenmark-life-sciences-ipo/articleshow/84978486.cms">Glenmark Life Sciences IPO: How to check allotment status, listing date and more</a>

India now has a fifth vaccine. Johnson & Johnson's single-dose COVID-19 shot gets government nod.

Inside Vivek Ramaswamy's intense, high-maintenance, and highly air-conditioned empire

Hi, welcome back to Insider Weekly, a roundup of some of our top stories. This is <a href="https://twitter.com/spriha">Spriha Srivastava</a>, filling in for Matt Turner. I am Insider's London bureau chief and international executive editor. I oversee our London and Singapore newsrooms and help Insider drive international expansion. We've got a lot to cover this week.<h3>On the agenda today:</h3><ul><li>Real-estate brokerage Compass <a href="https://www.businessinsider.com/compass-tech-team-layoffs-cost-cutting-share-price-2022-10">is in a precarious position</a>.</li><li>A tech founder rakes in $200,000 <a href="https://www.businessinsider.com/twitter-ghostwriter-silicon-valley-vc-venture-founder-san-francisco-2022-10">ghostwriting tweets for superstar VCs</a>.</li><li>It's probably time for <a href="https://www.businessinsider.com/mark-zuckerberg-should-quit-meta-facebook-new-metaverse-company-2022-10">Mark Zuckerberg to step down</a>.</li><li>Miami transplants are rejecting Florida traditions and <a href="https://www.businessinsider.com/designing-miami-ray-eilyn-jimenez-luxury-interior-design-florida-2022-10">radically transforming their homes</a>. </li></ul>But first: Senior healthcare reporter Shelby Livingston is giving us a behind-the-scenes look at her reporting on Elemy, a startup that insiders say often <a href="https://www.businessinsider.com/elemy-insiders-softbank-startup-overpromised-families-seeking-autism-care-2022-10">failed to provide</a> the quick access to autism care that it had promised. If this was forwarded to you, <a href="https://www.businessinsider.com/subscription/newsletter/insider-weekly">sign up here.</a> Download Insider's app <a href="https://www.insider.com/app">here.</a><h3><a href="https://www.businessinsider.com/elemy-insiders-softbank-startup-overpromised-families-seeking-autism-care-2022-10">Insiders say Elemy often couldn't deliver on its promise to provide quick access to autism care</a></h3><a href="https://www.businessinsider.com/elemy-insiders-softbank-startup-overpromised-families-seeking-autism-care-2022-10"></a>Startups that want to disrupt how healthcare is delivered are struggling as they try to grow fast, senior reporter Shelby Livingston writes. This week, I reported how SoftBank-backed Elemy aimed to transform autism care — but insiders say the $1.15 billion startup overpromised on its capacity to treat kids. More than 20 former and current employees spoke with me for <a href="https://www.businessinsider.com/elemy-insiders-softbank-startup-overpromised-families-seeking-autism-care-2022-10">this story</a>. Here's what they told me: <ul><li>To build up demand for its services, Elemy developed relationships with doctors to collect hundreds of patient referrals.</li><li>Employees said the startup left kids on waitlists because it struggled to hire clinicians.</li><li>"We were going and gobbling up referrals anyway just to stash them on our bench," one source said. </li></ul>One family, whose daughter Hope was recently diagnosed with autism, said their specialist recommended they try a type of autism therapy known as applied behavior analysis. The family heard from Elemy right after getting the diagnosis. After an initial assessment, Elemy told them they'd be in therapy in no more than eight weeks. It failed to deliver. <a href="https://www.businessinsider.com/elemy-insiders-softbank-startup-overpromised-families-seeking-autism-care-2022-10">Check out the full story here. </a>Now, on to this week's top stories.<h3><a href="https://www.businessinsider.com/compass-tech-team-layoffs-cost-cutting-share-price-2022-10">What's going on at Compass</a></h3><a href="https://www.businessinsider.com/compass-tech-team-layoffs-cost-cutting-share-price-2022-10"></a><div type="image" title="robert reffkin compass" height="2663" width="3550" msid="94898162" hostid="261" sizebytes="701486"></div>The real-estate brokerage Compass is in a tricky position. It's worth a fraction of its IPO valuation, it's never turned a profit, and employees say the former centerpiece of the business — its vaunted tech tools for agents — is falling apart.We spoke with four former employees who said the company's efforts to establish itself as one of the leading players in the multibillion-dollar proptech industry have been dashed.<a href="https://www.businessinsider.com/compass-tech-team-layoffs-cost-cutting-share-price-2022-10">Here's what Compass insiders told us.</a><h3><a href="https://www.businessinsider.com/twitter-ghostwriter-silicon-valley-vc-venture-founder-san-francisco-2022-10">Inside the life of a Twitter ghostwriter</a></h3><a href="https://www.businessinsider.com/twitter-ghostwriter-silicon-valley-vc-venture-founder-san-francisco-2022-10"></a><div type="image" title="Business man with Ghost emoji sitting in front of laptop with Twitter logos and money surrounding him 2x1 3" height="1200" width="1600" msid="94898164" hostid="261" sizebytes="115804"></div>Twitter is Silicon Valley's hottest and most important social club. To get in on the next big deal, investors must establish their credibility and appeal to startup founders. That's where ghostwriters come in.One ghostwriter who spoke with Insider is tasked with crafting tweets for top VCs, aiming with each quip to make the investor look good — all in 280 characters or less. The job takes him just five hours a week, and last year he raked in $200,000. <a href="https://www.businessinsider.com/twitter-ghostwriter-silicon-valley-vc-venture-founder-san-francisco-2022-10">Read his story here.</a><h3><a href="https://www.businessinsider.com/mark-zuckerberg-should-quit-meta-facebook-new-metaverse-company-2022-10">Is it time for Mark Zuckerberg to step down?</a></h3><a href="https://www.businessinsider.com/mark-zuckerberg-should-quit-meta-facebook-new-metaverse-company-2022-10"></a><div type="image" title="Black and white photo of Mark Zuckerberg in front of blue circle background 4x3" height="900" width="1200" msid="94898166" hostid="261" sizebytes="278754"></div>Senior correspondent Linette Lopez thinks so — and she thinks it's the only way for him to save his empire.In her latest analysis, Linette writes that Zuckerberg should let someone else manage Facebook, WhatsApp, and Instagram, and then use his wealth and venture-capital connections to launch a startup that can build out his vision of the metaverse.<a href="https://www.businessinsider.com/mark-zuckerberg-should-quit-meta-facebook-new-metaverse-company-2022-10">She explains why in her analysis. </a>Also read:<ul><li><a href="https://www.businessinsider.com/facebook-connect-metaverse-push-meta-wall-street-desperate-2022-10">Meta's 'desperate' metaverse push to build features like avatar legs has Wall Street questioning the company's future</a></li></ul><h3><a href="https://www.businessinsider.com/designing-miami-ray-eilyn-jimenez-luxury-interior-design-florida-2022-10">Miami homes are getting a fresh new look</a></h3><a href="https://www.businessinsider.com/designing-miami-ray-eilyn-jimenez-luxury-interior-design-florida-2022-10"></a><div type="image" title="Ray Jimenez is a man in a brown jacket, white shirt and necklace, wearing sunglasses and posing next to his wife Eilyn Jimenez who is wearing a yellow and white floral jacket and sunglasses" height="3793" width="5057" msid="94898168" hostid="261" sizebytes="1352030"></div>Gone are the days of simple white-on-white decor in Miami homes. Wealthy residents from New York and California moved to southern Florida in droves during the pandemic — and changed the Magic City's aesthetic, according to Ray and Eilyn Jimenez, two of the top interior designers in Miami. <a href="https://www.businessinsider.com/designing-miami-ray-eilyn-jimenez-luxury-interior-design-florida-2022-10">How newcomers have changed Miami's feel.</a><h3>This week's quote:</h3>"I was a total tomboy. I couldn't understand why I was born a girl. What the hell is going on? I want to carry a knife! I want to be lighting fires with a flint and steel! I want to be a pioneer!" <ul><li>"Mountain Girl" Carolyn Adams, Jerry Garcia's widow, in an interview with Insider. Read her account of <a href="https://www.businessinsider.com/mountain-girl-memoir-jerry-garcia-ken-kesey-merry-pranksters-sixties-2022-10">what the age of free love was really like</a>.</li></ul><h3>More of this week's top reads:</h3><ul><li>#MeToo accusers, 5 years later: 8 survivors who catalyzed the movement and <a href="https://www.insider.com/metoo-accusers-5-years-later-where-are-they-now-2022-10">where they are now.</a></li><li>The rich can use offshore life-insurance policies to pass down everything from stocks to yachts to their kids tax-free. <a href="https://www.businessinsider.com/wealth-private-placement-life-insurance-ppli-estate-tax-wyden-lombard-2022-10">Here's how it works.</a> </li><li>It's official: The pandemic <a href="https://www.businessinsider.com/covid-personality-jerks-mean-lazy-angry-natural-disaster-science-2022-10">turned us all into jerks</a>.</li><li>Gene-editing companies are growing, <a href="https://www.businessinsider.com/crispr-gene-editing-biotechs-keep-growing-despite-downturn-2022-10">even as biotech faces a downturn</a>.</li><li>Leaked Amazon slides instruct employees to <a href="https://www.businessinsider.com/leaked-amazon-slides-instruct-employees-to-double-down-frugality-2022-10">"double down on frugality." </a></li><li>Equifax said it fired employees for <a href="https://www.businessinsider.com/equifax-used-itsproduct-to-fire-employees-working-two-jobs-2022-10">working as many as 3 jobs at once.</a></li><li>Publicly funded data, America's best tool to fight inflation and prevent recessions, <a href="https://www.businessinsider.com/recession-watch-death-economic-data-cpi-inflation-unemployment-crash-worse-2022-10">is under threat</a>. </li></ul>Plus: Keep updated with the latest business news throughout your weekdays by checking out <a href="https://link.chtbl.com/therefresh">The Refresh from Insider</a>, a dynamic audio news brief from the Insider newsroom. <a href="https://link.chtbl.com/therefresh">Listen here tomorrow.</a>Edited by Jordan Parker Erb and Lisa Ryan. <a href="https://www.businessinsider.com/subscription/newsletter">Sign up for more Insider newsletters here.</a>

Insiders say Elemy often couldn't deliver on its promise to provide quick access to autism care

Good morning and welcome to <keyword id="9070519" type="UNKNOWN" weightage="60" keywordseo="10-things-in-tech">10 Things in Tech</keyword>. If this was forwarded to you, <a href="http://newsletter.businessinsider.com/join/4np/10-things-in-tech">sign up here</a>.Let's get started.1. Google will no longer track users as they browse the web. The move comes after the company's elimination of third-party cookies, which are used to target digital ads. <a href="https://www.businessinsider.com/google-to-stop-tracking-individuals-web-browsing-precision-ad-targeting-2021-3">This is what to know about the shift to protect users' privacy.</a>2. Oscar Health fell 10% in its trading debut. The buzzy health insurance firm priced its highly-anticipated IPO at $39 per share, raising $1.4 billion at a valuation of $9.5 billion. <a href="https://markets.businessinsider.com/news/stocks/oscar-health-stock-price-ipo-trading-debut-valuation-tk-billion-2021-3-1030146686">More details here.</a>3. A top bio<keyword id="6358815" type="UNKNOWN" weightage="60" keywordseo="tech">tech</keyword> VC and a top tech VC are making a $500 million bet in two of the hottest areas of healthcare. The investors launched a SPAC to tackle mental health and virtual healthcare. <a href="https://www.businessinsider.com/arch-venture-partners-and-general-catalyst-team-up-on-spac-2021-3">An exclusive look at what we know so far.</a><a href="https://www.businessinsider.com/arch-venture-partners-and-general-catalyst-team-up-on-spac-2021-3"></a>4. SpaceX attempted another high-altitude Starship flight. The rocket landed in one piece for the first time, but <a href="https://www.businessinsider.com/spacex-lands-starship-rocket-texas-without-explosion-first-time-2021-3">exploded on the pad</a> about 10 minutes later.5. Elizabeth Warren's proposed wealth tax takes aim at tech's heavyweights. The Ultra-Millionaire Tax Act would apply an annual 2% tax on individual net worths between $50 million and $1 billion. <a href="https://www.businessinsider.com/elizabeth-warren-wealth-tax-bezos-musk-gates-zuckerberg-billionaires-worth-2021-3">Here's how much tax Bezos, Musk, Gates, and Zuckerberg would owe.</a> 6. Parler claims it was valued at $1 billion before Amazon took it offline. The controversial social media site dropped its federal suit against AWS, but filed another in Washington state soon after. <a href="https://www.businessinsider.com/parler-amazon-lawsuit-dropped-aws-antitrust-web-host-2021-3">Here's what to know about the latest lawsuit.</a> 7. Want to go to Mars? Now you (kind of) can. NASA will be sending millions of names to Mars on its next mission in 2026, and anyone can sign up to have their name sent into space. <a href="https://www.businessinsider.com/mars-rover-perseverance-nasa-spaceflight-electron-beam-mission-spacecraft-planet-2021-3">We'll show you how.</a>8. Spam robocalls are on the rise - because they're incredibly profitable. Court decisions have paved the way for telemarketers to get away with these. <a href="https://www.businessinsider.com/why-so-many-spam-robocalls-how-to-stop-them-2021-3">Here's how to stop them.</a> 9. Zoom's explosive success is creating big opportunities for startups. Many are tying their success to the online streaming platform - and getting investors to put millions into apps and integrations. <a href="https://www.businessinsider.com/zoom-creating-new-opportunities-integration-app-developers-2021-3">An exclusive look at how Zoom has helped others thrive.</a>10. Google's AI firm DeepMind considered launching a food division with controversial vegan startup Hampton Creek. The now-abandoned partnership would have resulted in an AI-driven, plant-based food unit. <a href="https://www.businessinsider.com/google-deepmind-ai-food-hampton-creek-eat-just-2021-2">More on that strange almost-collaboration here. </a>Have an Amazon Alexa device? Listen to this update by searching "Business Insider" in your flash briefing settings.Compiled by Jordan Erb. Tips/comments? Email <a href="mailto:jerb@insider.com">jerb@insider.com</a> or tweet <a href="https://twitter.com/jordanparkererb">@JordanParkerErb</a>.Sign up for <a href="https://newsletter.businessinsider.com/join/free">more Insider newsletters here.</a>

10 things in tech you need to know today

Welcome to <keyword id="9884466" type="UNKNOWN" weightage="60" keywordseo="insider-cannabis">Insider Cannabis</keyword>, our weekly <keyword id="621414" type="PERSON" weightage="60" keywordseo="Newsletter">newsletter</keyword> where we're bringing you an inside look at the deals, trends, and personalities driving the multibillion-dollar global <keyword id="14728" type="ENTERTAINMENT" weightage="100" keywordseo="cannabis">cannabis</keyword> boom.<a href="http://newsletter.businessinsider.com/join/cultivated">Sign up here to get it in your inbox every week</a>.Happy Friday,I had an interesting chat with Cronos Chairman Michael Gorenstein and Gingko Bioworks CEO Jason Kelly about their new cannabinoid partnership.I'm far from a Ph.D. - and my knowledge of biosynthesis is scant-to-nonexistent - but what struck me about the partnership is that we could be moving into a world where we don't need actual <keyword id="40905" type="PERSON" weightage="60" keywordseo="Marijuana">marijuana</keyword> plants to produce the active compounds known as cannabinoids.The partnership will first focus on synthesizing CBG, a rare cannabinoid that's thought to have benefits for sleep and pain relief. Regular old marijuana plants produce CBG in low quantities, so if you are a consumer company - or a pharmaceutical giant - and you want to mass produce CBG, you need to find cheaper ways to do it.That's where brewer's yeast comes in. "You need to grow a big field of cannabis plants to get this vanishingly small amount of these key cannabinoids," Kelly told me. "And we said: Why don't we take that DNA code from the cannabis plant and move it over into an easier to grow organism like brewer's yeast."From there, Kelly says you put in a tank, brew it up, "and instead of beer coming out, you get CBG."Expect to see more scientific developments and patents coming out of this space. And, if you've been paying attention to our reporting, <a href="https://www.businessinsider.com/aurora-ceo-miguel-martin-genetics-will-dominate-cannabis-industry-2021-4">you'd know that IP is a hot commodity for acquisitions</a>. Other cannabis happenings from around the wide world: If you missed my chat with Sundial CEO Zachary George at last week's Benzinga Cannabis Capital Conference, <a href="https://www.youtube.com/watch?v=YzJYFaM9mwU">you can watch it here</a>. I also spoke at the GCI Summit with a panel of excellent folks <a href="https://summit.gcintelligence.com/">about the changing face of drug policy in the US</a> and the collateral consequences of cannabis convictions.New York Magazine <a href="https://www.instagram.com/p/CP3FIjfFDlK/?utm_medium=copy_link">asked mayoral candidates how much weed they smoke regularly</a> in an Instagram video. It's hilarious and worth a watch.Sen. Bernie Sanders <a href="https://twitter.com/natsfert/status/1403115544669216771?s=20">asked</a> Politico's cannabis policy reporter Natalie Fertig: "Are you stoned right now?" To which Fertig responded: "I am not stoned right now." <a href="https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zaW1wbGVjYXN0LmNvbS95MnJxWWJwNA/episode/YzNmMzQ3NjctOGJhMy00YzFlLThkNzEtYTMxZTBlNjU0NjRk?hl=en&amp;ved=2ahUKEwik-8nM94_xAhWidN8KHYuzBIgQjrkEegQIBBAF&amp;ep=6amp;ep=6">Listen to the exchange here</a>.Freelance cannabis writer and Insider contributor Andrew Ward released his new book, The Art of Marijuana Etiquette, this week. I'm super excited to get my hands on a copy, and <a href="https://www.simonandschuster.com/books/The-Art-of-Marijuana-Etiquette/Andrew-Ward/9781510754652">you can get yours here</a>. Let's get to it. - Jeremy Berke (<a href="https://twitter.com/jfberke">@jfberke</a>) &amp; Yeji (<a href="https://twitter.com/jesse_yeji?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor">@jesse_yeji</a>)If you like what you read, share this newsletter with your colleagues, friends, boss, spouse, strangers on the internet, or whomever else would like a weekly dose of cannabis news. Here's what we wrote about this week:<h3><a href="https://www.businessinsider.com/marijuana-stock-sundial-ceo-wallstreetbets-investors-helping-turn-around-company-2021-6">The CEO of hot cannabis firm Sundial shares how he capitalized on a wave of interest from Wall Street Bets to raise hundreds of millions of dollars and turn the company around</a></h3>Sundial Growers, a midsized Canadian <a href="https://www.businessinsider.com/cannabis">cannabis</a> cultivator, has become one of Reddit's favorite pot stocks. The company's CEO told Insider that intense interest from retail investors on Reddit's Wall Street Bets forum helped Sundial raise money and pay down debts.<h3><a href="https://www.businessinsider.com/cannabis-lawyers-deals-ma-legalization-decisions-shaping-industry-2021-6">7 top cannabis lawyers dish on the deals, disputes, and policy decisions shaping the $104 billion industry's future</a></h3>Insider spoke with top cannabis lawyers who've<a href="https://www.businessinsider.com/list-top-lawyers-law-firms-cannabis-marijuana-deals-2021"> worked on the industry's biggest deals.</a> They told us to expect more M&amp;A and more SPAC offerings in the coming months as well as increased clarity around the legal status of cannabis in the US. <h3><a href="https://www.businessinsider.com/cannabis-media-startup-civilized-relaunches-paying-workers-2021-6">Troubled cannabis-media startup Civilized is relaunching. The cofounder says she's trying to make good with unpaid workers and the company's biggest creditor.</a></h3>Civilized, a media startup in the cannabis industry, is relaunching this month after shuttering its doors in 2019 when a takeover offer fell through. CEO Terri Riedle said she was working to pay employees and satisfy the company's largest creditor.<h3><a href="https://www.businessinsider.com/cannabis-investment-firm-merida-capital-raising-250-million-2021-6">Prolific cannabis investment firm Merida Capital is raising $250 million for a new fund. Managing partner Mitch Baruchowitz shares why he's betting big on medical cannabis and the 'normalization' of the industry.</a></h3>Cannabis private-equity firm Merida Capital is raising a $250 million fund. Managing partner Mitch Baruchowitz told Insider that he's pursuing three key themes in Fund IV: medical cannabis, supply chain companies, and companies that address what the normalization of cannabis means for consumers. <h2>Executive Moves</h2><ul><li>JR Rahn, the cofounder and CEO of psychedelics company MindMed, is <a href="https://www.prnewswire.com/news-releases/mindmed-announces-chief-executive-officer-transition-301308922.html">leaving his role as CEO</a>, the company announced. Robert Barrow, chief development officer, will take over as CEO.</li></ul><h2>Deals, launches, partnerships, and IPOs</h2><ul><li><a href="https://aphrodite.health/">Aphrodite Health</a>, a company focused on developing psychedelic medicine to address women's mental and physical health, <a href="https://www.businesswire.com/news/home/20210604005455/en/First-Female-founded-Psychedelic-Biotech-Company-Launches">launched</a> last Friday.</li><li>Cannabis company Vireo Health is changing its name to Goodness Growth Holdings. It is also <a href="https://apnews.com/press-release/pr-newswire/health-technology-business-888fa83c5313f5ce7f6fb0b7b6a02ed9">launching R&amp;D efforts to develop psychedelic medicines</a>. </li><li>California cannabis company <a href="https://www.prnewswire.com/news-releases/herbl-announces-acquisition-of-blackbird-to-create-leading-multi-state-supply-chain-solution-in-cannabis-industry-301307409.html">HEBRL is acquiring Blackbird</a>, a Nevada-based cannabis distributor. The companies did not disclose financial terms of the transaction.</li><li>Cronos Group is partnering with Boston-based biotech Gingko Bioworks to <a href="http://thecronosgroup.gcs-web.com/news-releases/news-release-details/cronos-group-and-ginkgo-bioworks-amend-agreement-accelerate">produce cannabinoids at scale using yeast</a>. The first target for the partnership will be CBG, the companies said. </li><li>Tilray is launching a <a href="https://www.businesswire.com/news/home/20210608005394/en/Tilray-Announces-Launch-of-New-Medical-Cannabis-Brand-Symbios">medical cannabis brand called Symbios</a>. </li><li>Cannara Biotech is buying The Green Organic Dutchman's cultivation facility in Quebec <a href="https://www.prnewswire.com/news-releases/cannara-biotech-inc-enters-into-definitive-agreement-to-acquire-tgods-state-of-the-art-cultivation-and-manufacturing-facility-in-valleyfield-quebec-301310023.html">for $27 million plus $5.7 million funding</a> of certain deposit requirements, the companies said. </li><li>Toronto-based psychedelics company Field Trip Health has applied <a href="https://www.globenewswire.com/news-release/2021/06/08/2243503/0/en/Field-Trip-Health-Ltd-Applies-to-List-Its-Common-Shares-on-the-NASDAQ-Stock-Market.html">to list its shares on the Nasdaq</a>. <a href="https://www.businessinsider.com/first-vc-psychedelics-field-trip-ventures-canada-2019-6">Read our past coverage of Field Trip</a>.</li><li>Eoin Keenan, formerly of Prohibition Partners, is launching <a href="https://www.goodrays.com/">Goodrays</a>, a UK CBD-infused seltzer brand. </li></ul><h2>Research and data</h2><ul><li>The NFL is offering $1 million in grants to fund up to five research proposals into alternatives to opioids for pain management, including studies on cannabis, <a href="https://www.bloomberg.com/news/articles/2021-06-08/nfl-pledges-1-million-to-fund-cannabis-research-for-pain-relief">Bloomberg reports</a>.</li><li>A study of 20 healthy individuals published in the <a href="https://journals.lww.com/pain/Abstract/9000/Pain_response_to_cannabidiol_in_induced_acute.98051.aspx">Journal of the International Association of Pain</a> found that 800 mg of orally administered CBD did not affect perceptions of pain compared to a placebo.</li></ul><h2>Policy moves</h2><ul><li>Connecticut is convening a special session to vote on marijuana legalization before the end of June, <a href="https://www.courant.com/politics/hc-pol-marijuana-filibuster-vote-20210609-akmtinwi35bjtblzp6tu2fq74e-story.html">The Hartford Courant reports</a>. </li><li>Connecticut Gov. Ned Lamont signed a bill on Monday that would require the Department of Mental Health and Addiction Services to create a working group to "study the health benefits of psilocybin." <a href="https://www.marijuanamoment.net/connecticut-governor-signs-psychedelics-study-measure-as-he-awaits-marijuana-legalization-bill/">Read more</a> at Marijuana Moment.</li><li>Nevada Governor Steve Sisolak <a href="https://norml.org/news/2021/06/10/nevada-governor-signs-multiple-marijuana-reform-measures-into-law/">signed a bill</a> on Monday that would allow for consumption lounges in the state. The new law will take effect on October 1.</li><li>Two-thirds of Americans say they support the decriminalization of possession of most drugs, <a href="https://www.aclu.org/other/poll-results-american-attitudes-toward-war-drugs?initms_aff=nat&amp;initms_chan=soc&amp;utm_medium=soc&amp;initms=210609_fb&amp;utm_source=fb&amp;utm_campaign=&amp;utm_content=210609_racialjustice&amp;ms_aff=nat&amp;ms_chan=soc&amp;ms=210609_fbnat&amp;ms_chan=soc&amp;ms=210609_fb">according to a report from the nonprofit Drug Policy Alliance and ACLU</a>. </li></ul><h2>Earnings roundup</h2><ul><li>Jushi Holdings released its Q1 2021 <a href="https://ir.jushico.com/news-events/press-releases/detail/157/jushi-holdings-inc-reports-fourth-quarter-and-full-year">results</a> on Wednesday, reporting $41.7 million in net revenue and a $26.8 million loss.</li></ul><h2>Chart of the week</h2>The US hemp CBD market is expected to balloon to $16 billion by 2026, according to a report from Brightfield Group:<div type="image" title="Bar chart of the total US hemp CBD market from 2019 to 2026 with an expected growth to $16 billion in 2026" height="1040" width="1240" msid="83441201" hostid="261"></div><h2>What we're reading</h2><a href="https://www.wsj.com/articles/a-new-york-prison-locked-men-up-for-drugs-now-the-site-will-grow-marijuana-11622469601">A New York prison locked men up for drugs. Now the site will grow marijuana</a> (WSJ)<a href="https://www.businessinsider.com/washington-vaccine-weed-cannabis-marijuana-free-joint-2021-6">You can get a free joint if you get vaccinated in Washington State thanks to a 'Joints for Jabs' policy. Edibles and bongs are off limits.</a> (Insider)<a href="https://cannabitch.substack.com/p/thc-the-high-crustaceans">THC: The High Crustaceans</a> (Cannabitch)<a href="https://www.comoxvalleyrecord.com/business/comoxs-aurora-coast-home-to-one-of-the-worlds-largest-genetic-libraries-for-cannabis/?utm_source=dlvr.it&amp;utm_medium=twittertter">Comox's Aurora Coast home to one of the world's largest genetic libraries for cannabis</a> (Comox Valley Record)<a href="https://markets.businessinsider.com/news/stocks/cannabis-stocks-retail-investors-inflows-meme-tilray-amc-sundial-cronos-2021-6-1030497093">A rotation into cannabis stocks by retail investors has a lot more room to run as the latest meme-stock rally fades, research firm says</a> (Insider)

Merida Capital raising $250 million

<div class="KonaFilter image-container display-table"><div><div class="image on-image">Netflix</div></div></div>When you sit down to watch a TV show or movie on Netflix, you're <a href="https://www.businessinsider.com/netflix-and-rivals-are-racing-to-build-better-recommendation-engines-2019-7">helping fine tune the streaming giant's recommendation engine</a>. As BI reporter Ashley Rodriguez reported this week, algorithms sort through the thousands of titles available to determine which to display, in what order, and with what artwork or other features, based on your interests. I might see one show and one set of artwork, my neighbors another. And as more and more of us watch more hours of entertainment on platforms like Netflix, Netflix should get better and better at showcasing what we might enjoy most. Data gleaned from viewers' participation in new interactive shows like "Black Mirror: Bandersnatch" could take that a step further, helping <a href="https://www.businessinsider.com/netflix-and-rivals-are-racing-to-build-better-recommendation-engines-2019-7">Netflix better understand why people are drawn to certain attributes in content, such as the emotional tonality of characters</a>.YouTube's algorithms similarly have the power to put a show or star in front of millions of eyeballs. BI reporter Amanda Perelli talked to Jennelle Eliana, who has posted only three videos to the video-sharing site yet already has 1.5 million subscribers. How? YouTube's algorithm picked up her first two videos and recommended them to its users, which is <a href="https://www.businessinsider.com/youtuber-jennelle-eliana-rapidly-gained-million-subscribers-interview-2019-7">the likely cause of her instant success.</a>(Unsurprisingly, creators have found ways to game the algorithm. Perelli also talked to YouTube star MrBeast, who has 22 million subscribers, <a href="https://www.businessinsider.com/how-youtube-star-mr-beast-uses-keywords-to-get-trending-2019-7">about his use of keywords to maximize views</a>.)Old-school TV channels are getting in on the act, too, with MTV using insights from tech giants to build buzz for a reality-TV revival. When MTV premiered "The Hills: New Beginnings" in June, the marketing team worked with Google's insights lab to test content on YouTube.MTV found that "The Hills" theme song, "Unwritten," resonated with audiences, regardless of whether they had seen the show. MTV then partnered with artist Natasha Bedingfield and social music app Smule to record a version of the song that fans <a href="https://www.businessinsider.com/mtv-marketing-plan-for-the-hills-google-insights-new-audiences-2019-7">could sing along with and share across social channels</a>.And in the ad world, tracking what you watch is becoming big business. Lauren Johnson talked to TV-tech entrepreneur John Hoctor, the CEO of buzzy TV-measurement firm Data Plus Math, <a href="https://www.businessinsider.com/data-plus-maths-john-hoctor-talks-150-million-liveramp-acquisition-2019-7">who sold his company for $150 million</a>."Advertisers know that TV works, but they haven't had the granular reporting to understand what parts of it were working better than others," Hoctor said. In short, remember: You're being watched when you watch. -- Matt<h2>Quote of the week</h2>"I'm interested in - and looking to acquire - lots of companies who are going and reprogramming people's DNA." - Tej Kohli, a tech billionaire and chairman of Tej Kohli Ventures, on his interest in DNA reprogramming. He said his children will live to at least 125 years old <a href="https://www.businessinsider.com/tech-billionaire-tej-kohli-says-children-will-live-to-125-2019-7">because of tiny robots, DNA reprogramming, and artificial blood</a>. <h2>In conversation</h2><ul><li>Marley Jay talked to JR Gondeck, who was just named the fourth-best wealth adviser under the age of 40 by Forbes. He said millions of millennials are <a href="https://www.businessinsider.com/college-savings-advice-from-top-rated-millennial-wealth-manager-2019-7">making a mistake by investing in 529 savings plans to pay for their kids' college</a>.</li><li>Dan DeFrancesco talked to Samik Chandarana, the head of data analytics, applied artificial intelligence, and machine learning for JPMorgan's corporate and investment bank. He explained what the bank's doing <a href="https://www.businessinsider.com/jpmorgan-artificial-intelligence-machine-learning-2019-7">to</a><a href="https://www.businessinsider.com/jpmorgan-artificial-intelligence-machine-learning-2019-7"> avoid costly mistakes in AI and machine learning</a>.</li><li>Jeremy Berke talked to Hershel Gerson, CEO of ELLO Capital, a new boutique investment bank focused on the cannabis business, about the competitive cannabis landscape in the US, <a href="https://www.businessinsider.com/wall-street-alumni-launch-ello-capital-for-cannabis-ma-deals-2019-7">why he thinks the market is underserved, and how he'll fill his pipeline of deals</a>.</li><li>Ben Pimental talked to Arvind Krishna, IBM senior vice president in charge of cloud and cognitive software. He revealed the game plan for its $34 billion Red Hat acquisition and <a href="https://www.businessinsider.com/ibm-hybirid-cloud-red-hat-arvind-krishna-2019-7">says it'll give it "massive reach" in a $1.2 trillion cloud market</a>. </li><li>Rosalie Chan talked to Dustin Moskovitz, cofounder and CEO of Asana, about the firm's new product to address worker burnout. He said it <a href="https://www.businessinsider.com/asana-workload-facebook-cofounder-dustin-moskovitz-2019-7">uses a concept he learned from his time as cofounder of Facebook</a>.</li><li>Lucia Moses talked to Best Western CMO Dorothy Dowling about the company's use of AI to personalize ads. She said the <a href="https://www.businessinsider.com/best-western-is-using-artificial-intelligence-to-personalize-ads-2019-7">results are crushing the industry average</a>.</li></ul><h2>Finance and Investing</h2><a href="https://www.businessinsider.com/london-stock-exchange-ceo-david-schwimmer-profile-2019-7">How a little-known Goldman Sachs partner took over the LSE and orchestrated an industry rattling $27 billion buyout</a>As a Goldman Sachs banker in 2005, David Schwimmer offered some prescient advice: He helped the New York Stock Exchange buy the electronic-trading platform Archipelago Holdings, ending NYSE's 200 years of mutual ownership and moving it beyond the realm of human traders.<a href="https://www.businessinsider.com/sec-steps-up-scrutiny-of-private-stakes-held-by-funds-2019-7">The SEC is stepping up scrutiny of mutual funds that have poured money into unicorns like WeWork and Airbnb</a>The Securities and Exchange Commission is stepping up scrutiny of mutual fund investments in private companies, according to people with knowledge of the agency's interest.<a href="https://www.businessinsider.com/how-lone-pine-capital-stock-picks-winners-market-disruptors-2019-7">Lone Pine Capital stock-pickers explain why they're investing in Tiffany and Nintendo and how they value "disruptors" like Beyond Meat.</a>What do Nintendo, World Wrestling Entertainment, and Tiffany &amp; Co have in common?<h2>Tech, Media, Telecoms</h2><section><a href="https://www.businessinsider.com/how-vmware-became-the-secret-winner-of-the-cloud-wars-2019-7">How VMware became a secret superpower in the cloud wars and why Amazon Web Services should not be happy but Google and Microsoft are thrilled</a>Earlier this week, Google's cloud boss, Thomas Kurian, <a href="https://cloud.google.com/blog/topics/partners/vmware-cloud-foundation-comes-to-google-cloud">triumphantly announced</a> he had expanded Google's partnership with VMware - bringing VMware's core technology, and hopefully its customers, to Google Cloud.<a href="https://www.businessinsider.com/cloudflare-plans-to-ipo-in-september-2019-7">$3.2 billion cyber company Cloudflare is eyeing a September IPO, just months after raising a $150 million funding round</a>Cloudflare, a company that speeds up content delivery and protects websites from outside attackers, has its eye on a September IPO, according to people familiar with the company.<a href="https://www.businessinsider.com/procter-and-gambles-head-of-media-is-going-to-snap-2019-7">A top P&amp;G advertising exec who overhauled how the CPG giant works with its agencies is leaving for Snapchat</a>Craig Stimmel, Procter &amp; Gamble's head of digital media and global partnerships, is leaving after more than eight years to be Snap's head of brand partnerships based in Chicago, sources familiar with the move told Business Insider.</section><h2>Healthcare, Retail, Transportation</h2><a href="https://www.businessinsider.com/modernas-dave-johnson-on-using-machine-learning-for-overlooked-areas-2019-7">A $4.5 billion biotech working on tech-driven cancer treatments told us how it's using AI in areas rivals are ignoring, and why companies that aren't could struggle</a>For biotech company Moderna, which went public last year in the <a href="https://www.businessinsider.com/biotech-moderna-prices-initial-public-offering-2018-12">biggest biotech IPO in history,</a> the emphasis is as much on the tech as the biology.<a href="https://www.businessinsider.com/15-dtc-brands-that-will-blow-up-in-2019-2019-7">Investors from Greycroft, Science, Lerer Hippeau, and others who control millions of dollars name the direct-to-consumer startups that will blow up this year</a>Many consumer products categories face attacks from direct-to-consumer upstarts that have upended everything from how we sleep (Casper) to how we buy glasses (Warby Parker).<a href="https://www.businessinsider.com/uber-employees-reveal-how-they-were-fired-2019-7">Uber marketing employees describe this week's 'bloodbath' when the company laid off 400 employees in more than a dozen countries this week</a>On Monday morning, around 8 am California time, hundreds of Uber employees around the world received an ominous email from Jill Hazelbaker, the ride-hailing company's head of marketing, communications, and public policy.<a href="https://www.businessinsider.com/intelligence/top-10-trends-in-digital-media?IR=T&amp;itm_source=businessinsider&amp;itm_medium=ctgr_bii&amp;itm_term=ctgr_leadgen&amp;itm_content=netflix&amp;itm_campaign=top-10-trends-in-digital-media"></a> <div class="margin-top"> <h3>NOW WATCH: <a href="https://www.businessinsider.com/amazon-ceo-jeff-bezos-richest-person-net-worth-billions-2018-12">Jeff Bezos is worth over $160 billion - here's how the world's richest man makes and spends his money</a></h3> <div> </div> </div>

What you're watching, mutual fund scrutiny, and Uber's 'bloodbath'

<div class="KonaFilter image-container display-table"><div><div class="image on-image">Samantha Lee/Business Insider</div></div></div><ul class="summary-list"><li>Drug discovery is one of the most significant areas of promise for AI in data-rich healthcare, but experts warn that too much hype is risky.</li><li>Biotech Moderna has since its launch taken a tech-forward approach to health solutions, including developing personalized therapies, and modeling variables such as clinical trial duration.</li><li>This article includes an overview of AI in health, including the top three trends to watch, and how biotech Moderna applies AI to free up scientists to make discoveries. </li><li>Read how AI is transforming retail, transporation, consumer technology, and more in other articles from our special report, <a href="https://www.businessinsider.com/how-ai-is-changing-everything-2019-7">How AI is Changing Everything</a>.</li></ul>For the pharmaceutical industry, which is staked out on the premise of finding, developing, and ultimately selling advanced new medications, there is no greater challenge than the sheer unpredictability of that task.Technology known as machine learning and artificial intelligence could change all that, its boosters say.That's because in an industry with massive data sets at its disposal, machine learning and AI tech is able to ingest and make sense of it all, informing better predictions about complex subjects like which experimental drugs are most likely to successfully treat patients. In the pharmaceutical industry, where productivity from the research and development activities that lead to new drugs has been <a href="https://www2.deloitte.com/uk/en/pages/press-releases/articles/pharma-r-and-d-returns-fall-to-lowest-level-in-nine-years.html">on the decline</a> for <a href="https://endpts.com/pharmas-broken-business-model-an-industry-on-the-brink-of-terminal-decline/">decades</a>, that's desperately needed. Swiss drug giant Novartis and its CEO Vas Narasimhan have touted the potential of machine learning and AI - with executive Jay Bradner telling Business Insider that AI is <a href="https://www.businessinsider.com/jay-bradner-on-how-novartis-is-using-ai-for-drug-research-development-2019-1">"the next great tool"</a> to find new medicines early this year - before pulling back some more recently. Sanofi, which recently named its first chief digital officer, is using AI to develop digital therapeutics that it hopes can help with conditions like depression. The biotech Moderna is using it to make personalized cancer vaccines custom-crafted for each patient.But this is also an area where hype is high. Critics say that talk is at odds with the tech's accomplishments. They note, for example, that no one drug has yet been developed using AI."I think it's really important in this space to avoid excess hype. A lot of people fall into, 'this is going to change everything and discover drugs in 12 months.' Nonsense. It discredits the field when people do that," says Daphne Koller, who has a background as an AI researcher at Stanford and serves as founder and CEO of machine learning startup <a href="https://www.businessinsider.com/bezos-startup-gilead-nash-liver-drugs-insitro-2019-4">Insitro</a>.Insitro is developing better models for which to test out new drugs, and as part of that recently announced a partnership with biotech Gilead on drugs for a disease that can lead to liver failure. But Koller, who previously served as chief computing officer of <a href="https://www.businessinsider.com/google-calico-ancestry-dna-genetics-aging-partnership-ended-2018-7">Calico</a>, Google's life-extension spinoff, also says it's unrealistic at this stage to expect an AI drug, given that the drug development process can take 10 years. In the biopharmaceutical industry, "we're just starting on this journey," she says. The perils of hype were seen with IBM, which famously declared that its AI system Watson could better treat cancer. But the computing company's efforts to apply AI in healthcare have fallen short of expectations, according to reports from STAT and <a href="https://www.wsj.com/articles/ibm-bet-billions-that-watson-could-improve-cancer-treatment-it-hasnt-worked-1533961147">The Wall Street Journal</a>. IBM also stopped selling a Watson-based product for use in pharmaceutical drug discovery because of subpar financial performance, STAT <a href="https://www.statnews.com/2019/04/18/ibm-halting-sales-of-watson-for-drug-discovery/">reported</a> in April. <div class="KonaFilter image-container display-table"><div><div class="image on-image">Lauren F. Friedman / Business Insider</div></div></div><h2>Top 3 opportunities for health and AI</h2><h3>Biopharma companies' operational and planning needs: Pre-launch</h3>The biotech Moderna's senior director of informatics, Dave Johnson, makes the compelling case that smaller problems at drug companies, like internal planning for operations like manufacturing, are getting overlooked when it comes to this technology. <h3>Discovering new drugs: Growing</h3>Drug companies and new startups are using this tech to find out which chemicals have promise as medicines, because it gives them the firepower to screen one million or more compounds, and predict which aspects of them could be useful. <h3>Securing data and making predictions from images: Mature</h3>Images of things like scientific experiments have always been important sources of information for biopharmaceutical companies, but machine learning has given the industry new tools for collecting data from imaging and making predictions based on that about, say, how a chemical compound works on cells in the body, or whether a given molecule might be unsafe in the body.<h2>Moderna uses AI to crack tough business decisions and aid development of personalized medicines</h2>For Moderna, the Cambridge, Massachusetts-based biotech company that went public last year in the <a href="https://www.businessinsider.com/moderna-therapeutics-biotechnology-initial-public-offering-record-2018-12">biggest biotech IPO</a> in history, a tech-driven approach to medicine is at its very core, from the tablets that monitor operations on the floor of its Norwood, Massachusetts manufacturing facility, to the algorithms that are used in its experimental cancer vaccines. AI is being used across the biopharmaceutical industry to take on some of its most persistent challenges. But Dave Johnson, Moderna's senior director of informatics, says that "the success we've had has been not focusing on these large moonshot programs but all the little things that make it really hard for our scientists to do their jobs" so they "can focus on their core jobs of being innovative." "I think there are a lot of applications of machine learning, AI, that people are ignoring," he said. Those smaller problems, which are achievable, get overlooked, "and I think a lot of companies in the industry are going to struggle with that."Moderna has been able to see and seize those opportunities because the company digitized all its operations from the very beginning, which allowed it to generate data enabling the use of algorithms, he said. For instance, Moderna is developing experimental products called personalized cancer vaccines that are being tested out for conditions like melanoma, and must be custom made for each patient. Because of that, and because patients enroll in research trials at variable times, planning the manufacturing process for the vaccines, from capacity for orders to even aspects like how much raw material the biotech needed, was especially complicated. The biotech also wanted to know what would happen if aspects were changed, and how much that would affect the product. So Moderna turned to an algorithm, feeding in metrics from research trials to simulate hundreds of trials with thousands of pretend patients, asking questions like, "What if we change this timeline from five days to three days? What would that mean?" Johnson said. The results allowed Moderna to match its manufacturing capacity to its needs, including through making large, crucial decisions about where to invest capital funds. "Before we had this tool, they were kind of guessing," he said.The machine learning-based approach allows Johnson and team to supply decision-makers with concrete metrics, like what percentage of patients will need a particular dose. Those, in turn, go into designing a research trial and ensuring capacity is large enough to meet patient needs, without spending so much on capital that expensive manufacturing capacity gets wasted. At Moderna, digital initiatives are emphasized at every level, from the company's Chief Digital Officer, Marcello Damiani, to the amount of internal resources that are available, Johnson says. This particular project began when Moderna's clinical team, which takes charge of all matters related to its research programs, was having difficulty figuring out where to begin. Johnson's group analyzed both the problem and how achievable it was. It also considered the project's value, or how great the return on investment could be. Quantifying that was hard. But because the project involved large capital decisions being made around the company's future, "it was clear that it was an overwhelming return on investment," Johnson says. So the team set it into motion, with work beginning in February of 2018, all done in house. The initial release came about a month later. The algorithm has been used consistently in the time since for various projects around the company, including to plan for Moderna's phase 2 research.Because this project addressed a more or less straightforward problem, and could be handled with a simple algorithm, trained using a forecasting technique and the right data, Johnson doesn't recall any large hurdles.But that hasn't been the case with every algorithm. The duration of AI projects can be highly variable, depending on their complexity and the availability of relevant data, according to Johnson. One especially tenacious, complex problem, for instance, has held up one project for years. The AI solution Johnson and his team devised has been working and being used to make key decisions across four different teams at the company, including the manufacturing unit, he says. That can be tracked easily, because Moderna came up with a plan and can follow whether there are any discrepancies as research develops.Johnson says that "if there was a mismatch we would absolutely see that, and so far we haven't seen those challenges."<div class="KonaFilter image-container display-table"><div><div class="image on-image">Cody Glenn / ContributorDaphne Koller, CEO and Founder, Insitro</div></div></div><a href="http://www.businessinsider.com/intelligence/ai-in-us-healthcare?IR=T&amp;utm_source=businessinsider&amp;utm_medium=ctgr&amp;utm_term=ctgr_leadgen&amp;utm_content=dhealth_ctgr_leadgen&amp;utm_campaign=dhealth_ctgr_leadgen_ai_in_us_healthcare"></a></hr> <div class="margin-top"> <h3>NOW WATCH: <a href="https://www.businessinsider.com/most-dangerous-deadly-animal-2017-6">Sharks aren't the deadliest creatures on Earth. Here are the top 10.</a></h3> <div> </div> </div>

You Searched For "how to apply windlas biotech ipo" and got 7 results

India now has a fifth vaccine. Johnson & Johnson's single-dose COVID-19 shot gets government nod.

PTI

Inside Vivek Ramaswamy's intense, high-maintenance, and highly air-conditioned empire

Katherine Long,Jack Newsham,M…

Insiders say Elemy often couldn't deliver on its promise to provide quick access to autism care

Jordan Parker Erb,Spriha Sriv…

10 things in tech you need to know today

Jordan Parker Erb

Merida Capital raising $250 million

Jeremy Berke,Yeji Jesse Lee

What you're watching, mutual fund scrutiny, and Uber's 'bloodbath'

Matt Turner

The $1.2 trillion pharma industry has ambitions for AI technology, but 'people are ignoring' a lot of its uses

Emma Court